[1] El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am, 2019, 28(4):587-599. [2] Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol, 2020, 72(2):353-363. [3] Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol, 2020, 72(2):364-377. [4] Saleh M, Virarkar M, Bura V, et al. Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings. Abdom Radiol (NY), 2020, 45(11):3662-3680. [5] Nomi T, Hirokawa F, Kaibori M, et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: a multi-centre propensity score-based analysis. Surg Endosc, 2020, 34(2):658-666. [6] Viganò L, Laurenzi A, Solbiati L, et al. Openliver resection, laparoscopic liver resection, and percutaneous thermal ablation for patients with solitary small hepatocellular carcinoma (≤30 mm): review of theliterature and proposal for a therapeutic strategy. Dig Surg, 2018, 35(4):359-371. [7] Urade T, Sawa H, Iwatani Y, et al. Laparoscopic anatomical liver resection using indocyanine green fluorescence imaging. Asian J Surg, 2020, 43(1):362-368. [8] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版).中华消化外科杂志,2017,16(7):13. [9] Lu JC, Zeng HY, Sun QM, et al. Distinct PD-L1/PD1profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors. Theranostics, 2019,9(16):4678-4687. [10] Bagante F, Spolverato G, Merath K, et al. Intrahepatic cholangiocarcinoma tumor burden:a classification and regression tree model to define prognostic groups after resection. Surgery, 2019,166(6):983-990. [11] Squires MH, Cloyd JM, Dillhoff M, et al. Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol, 2018,12(7):671-681. [12] Agarwal V, Divatia JV. Enhanced recovery after surgery in liver resection: current concepts and controversies. Korean J Anesthesiol, 2019,72(2):119-129. [13] Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, et al. Laparoscopicversus open resection for colorectal liver metastases: The OSLO-COMET randomized controlled trial. Ann Surg, 2018, 267(2):199-207. [14] Li J, Xing J, Yang Y, et al. Adjuvant131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre,open-label, phase 2 trial. Lancet Gastroenterol Hepatol, 2020, 5(6):548-560. [15] Haruna K, Katsura Y, Takeda Y, et al. Analysis oflaparoscopic liver resection for hepatocellular carcinoma with cirrhosis. Gan To Kagaku Ryoho, 2020, 47(13):2388-2390. [16] Haber PK, Wabitsch S, Kästner A, et al. Laparoscopicliver resection for intrahepatic cholangiocarcinoma: a single-center experience. J Laparoendosc Adv Surg Tech A, 2020, 30(12):1354-1359. [17] Al-Saif FA, Aldekhayel MK, Al-Alem F, et al. Comparison study between open and laparoscopic liver resection in a Saudi tertiary center. Saudi Med J, 2019, 40(5):452-457. [18] Zhang Y, Dou C, Wu W,et al. Total laparoscopic versus open radical resection for hilar cholangiocarcinoma. Surg Endosc, 2020, 34(10):4382-4387. [19] 秦胜利,董妍,孙艺.肝内胆管癌患者术后预后研究.实用肝脏病杂志,2018,21(4):2. [20] Ypsilantis P, Lambropoulou M, Anagnostopoulos K, et al. Effect of laparoscopic liver resection versus the open technique on hepatocyte regenerating activity in the rat. Surg Endosc, 2020, 34(11):4812-4817. [21] Hou H, Zhou D, Cui X, et al. Laparoscopicliver resection ameliorates the postoperative liver function impairment for hepatocellular carcinoma patients. Surg Laparosc Endosc Percutan Tech, 2020, 30(1):69-73. [22] 周兵,张建淮,刘斌,等.腹腔镜与开放性肝切除术治疗小肝癌的远期疗效.中华肝胆外科杂志,2017,23(1):8-11. [23] 符荣党,李杰原,王峰杰,等.腹腔镜与开腹左半肝切除治疗肝细胞癌临床对比研究.中华肝脏外科手术学电子杂志,2018,7(6):477-481. [24] Aghayan DL, Kazaryan AM, Dagenborg VJ, et al. Long-term oncologic outcomes after laparoscopic versus open resection for colorectal liver metastases : A randomized trial. Ann Intern Med, 2021, 174(2):175-182. |